Dulaglutide

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1210 publications

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

Journal: The American journal of managed care
Published: June 23, 2026

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Journal: Annals of internal medicine
Published: June 15, 2026

GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.

GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: May 29, 2026

Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review.

Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review.

Journal: Cureus
Published: May 17, 2026

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Treatment After Liver Transplantation: A Hypothesis-Generating Case Report.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Treatment After Liver Transplantation: A Hypothesis-Generating Case Report.

Journal: Cureus
Published: May 12, 2026

Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes.

Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes.

Journal: International journal of clinical pharmacology and therapeutics
Published: May 06, 2026

Sensitive RP-LC Method Enabling PTM-Specific Quality Control and MS-Compatible Characterization of Fc-Containing GLP-1 Therapeutics.

Sensitive RP-LC Method Enabling PTM-Specific Quality Control and MS-Compatible Characterization of Fc-Containing GLP-1 Therapeutics.

Journal: Journal of the American Society for Mass Spectrometry
Published: May 06, 2026

In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y.

In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y.

Journal: Annals of internal medicine
Published: May 04, 2026

Beyond the GH-IGF-1 Axis: A Network Perspective Integrating Clinical Observations and Mechanistic Insights.

Beyond the GH-IGF-1 Axis: A Network Perspective Integrating Clinical Observations and Mechanistic Insights.

Journal: Endocrine connections
Published: May 01, 2026

Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.

Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.

Journal: Neurology
Published: April 30, 2026

Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial.

Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial.

Journal: Neurology and therapy
Published: April 28, 2026

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.

Journal: Current atherosclerosis reports
Published: April 24, 2026
Showing 1-12 of 1,210

Last Updated: 06/30/2026